BioWorld

Sep. 9, 2009

View Archived Issues

Regulatory Submissions Data System Integration: How to Do it

NewCo News: Kinaris Targeting Myosins with Allosteric Inhibitors

Other News To Note

Financings Roundup

Clinic Roundup

Appointments And Advancements

Opexa Gets Boost on Positive Analysis of Tovaxin MS Data

Shares of Opexa Therapeutics Inc. soared 270 percent Tuesday on news of a positive complete analysis of its Phase IIb drug for multiple sclerosis, Tovaxin. (BioWorld Today) Read More

Osiris Sees Prochymal Promise Despite Phase III GvHD Failures

Today's news in brief

BioWorld

BioWorld briefs for June 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 16, 2025.

Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA

BioWorld

During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...

23andme founder-led group outbids Regeneron for company

BioWorld

The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...

Elevidys’ second liver death hits Sarepta, sends DMD ripples

BioWorld

How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...